A Patient withThrombotic Thrombocytopenic Purpura Who Completely Fulfills All Pentad: A Case Report

Main Article Content

Chalothorn Wannaphut
Somchai Insiripong

Abstract

Abstract:


Thrombotic thrombocytopenic purpura (TTP) is a rare but serious disease that is characterized by the microangiopathic hemolytic anemia (MAHA), thrombocytopenia, neurologic abnormalities, kidney impairment and fever, the so-called pentad. So far it has been rarely recognized among Thai patients. And herein, we reported one patient who completely fulfilled all pentad of TTP which was confirmed by the severe deficiency of ADAMTS13 activity. He was a 70-year-old Thai man who suddenly developed confusion and disorientation within a day. Besides confusion, the physical examination revealed fever and frank pallor. The blood tests included Hb 7.4 g%, WBC 7,700/mm3, platelet 17,000/mm3, with the MAHA picture on the peripheral blood smear, reticulocyte 4.1%, creatinine 1.3 mg%, GFR 55 ml/min/1.73 m2, and the ADAMTS13 factor activity was less than 3%.The computerized tomography of the brain revealed unremarkable study. He was diagnosed as having TTP therefore he was treated with the daily plasmapheres is. The complete fulfillment of all pentad of TTP is not commonly found in most cases who always present with only MAHA, thrombocytopenia with ADAMTS13 deficiency. He dramatically responded to therapy with the complete recovery of all pentad. The plasmapheresis is the highly effective method of treatment for TTP probably because it could remove the large and ultra-large von Willebrand Factor, remove the ADAMTS13 inhibitors and proteolytic inactivators, and replenish ADAMTS13 that is severely lacked in most cases of TTP.

Article Details

How to Cite
Wannaphut, C., & Insiripong, S. . . (2024). A Patient withThrombotic Thrombocytopenic Purpura Who Completely Fulfills All Pentad: A Case Report. Maharat Nakhon Ratchasima Hospital Journal, 37(3), 175–178. Retrieved from https://he04.tci-thaijo.org/index.php/MNRHJ/article/view/1637
Section
Case Report

References

George JN, Al-Nouri ZL. Diagnostic and therapeutic challenges in the thrombotic thrombocytopenic purpura and hemolytic uremic syndromes. Hematology Am Soc Hematol Educ Program 2012; 2012: 604-9.

พลรังสิตย์ กรุดภู่, เอกรัฐ รัฐฤทธิ์ธำรง, ลลิตา นรเศรษฐ์ธาดา, อดิศักดิ์ ตันติวรวิทย์, ชาตรี ชัยอดิศักดิ์โสภา, วีระศักดิ์ นาวารวงศ์. ลักษณะทางคลินิกของผู้ป่วย Thrombotic thrombocytopenic purpura (TTP) ในโรงพยาบาลมหาราชนครเชียงใหม่. วารสารโลหิตวิทยา และเวชศาสตร์บริการโลหิต 2556; 23: 217-26.

Chemnitz JM, Hallek M, Scheid C. Long-term efficacy of rituximab treatment in thrombotic thrombocytopenic purpura. Eur Oncol Haematol 2011; 7: 143-7.

Burrus TM, Wijdicks EF, Rabinstein AA. Brain lesions are most often reversible in acute thrombotic thrombocytopenic purpura.Neurol 2009; 73: 66-70.

Ben-Yehuda D, Rose M, Michaeli Y, Eldor A. Permanent neurological complications in patients with thrombotic thrombocytopenic purpura. Am J Hematol 1988; 29: 74-8.

Butros LJ, Bussel JB. Intracranial hemorrhage in immune thrombocytopenic purpura: a retrospective analysis. J Pediatr Hematol Oncol 2003; 25: 660-4.

Franchini M, Mannuccio Mannucci P. Advantages and limits of ADAMTS13 testing in thrombotic thrombocytopenic purpura. Blood Transfus 2008; 6: 127-35.

Kremer Hovinga JA, Lammle B. Role of ADAMTS13 in the pathogenesis diagnosis and treatment of thrombotic thrombocytopenic purpura. ASH Education Book 2012; 2012: 610-6.

Nguyen TC, Kiss JE, Goldman JR, Carcillo JA. The role of plasmapheresis in critical illness. Crit Care Clin 2012; 28: 453-68.